MicroRNA-664 targets paired box protein 6 to inhibit the oncogenicity of pancreatic ductal adenocarcinoma Retraction in /10.3892/ijo.2022.5380

Wang,Qi; Wang,Jiaqi; Niu,Songtao; Wang,Songsong; Liu,Yibin; Wang,Xiaoya

doi:10.3892/ijo.2019.4759

MicroRNA-664 targets paired box protein 6 to inhibit the oncogenicity of pancreatic ductal adenocarcinoma

Retraction in: /10.3892/ijo.2022.5380

Authors:
- Qi Wang
- Jiaqi Wang
- Songtao Niu
- Songsong Wang
- Yibin Liu
- Xiaoya Wang
View Affiliations

Affiliations: Department of Emergency, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: March 19, 2019 https://doi.org/10.3892/ijo.2019.4759
Pages: 1884-1896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal expression of microRNAs (miRNAs or miRs) with oncogenic or tumor‑suppressive roles in pancreatic ductal adenocarcinoma (PDAC) has been widely reported in recent years, and these dysregulated miRNAs are implicated in the formation and progression of PDAC. Therefore, an investigation into the functional roles of miRNAs in PDAC may facilitate the identification of effective therapeutic targets. miRNA‑664 (miR‑664) has been found to be aberrantly expressed and to play crucial roles in several human cancer types. However, the expression pattern and functional roles of miR‑664 in the malignant capacity of PDAC have yet to be elucidated. In this study, the results revealed that miR‑664 was clearly downregulated in PDAC tissues and cell lines. The low miR‑664 expression was strongly associated with pathological T stage and lymph node metastasis of the patients with PDAC. Patients with PDAC with a low miR‑664 expression had a poorer overall survival and a worse disease‑free survival than those patients with a high miR‑664 level. Functional experiments suggested that exogenous miR‑664 expression suppressed the growth and metastasis of PDAC cells in vitro, whereas miR‑664 downregulation exerted the opposite effects. In addition, miR‑664 suppressed the tumor growth of PDAC cells in vivo. Mechanistically, paired box protein 6 (PAX6) was identified as a direct target gene of miR‑664 in PDAC cells. Furthermore, PAX6 was upregulated in PDAC tissues, and its upregulation inversely correlated with miR‑664 levels. Moreover, the silencing of PAX6 mimicked the effects of miR‑664 upregulation in PDAC cells, and the recovered expression of PAX6 eliminated the effects of miR‑664 on PDAC cells. Notably, miR‑664 could inhibit the activation of PI3K/Akt pathway in PDAC cells in vitro and in vivo. Cumulatively, these results indicate an important role of the miR‑664/PAX6 pathway in suppressing the aggressiveness of PDAC cells, suggesting that miR‑664 may be an attractive therapeutic target for the treatment of patients with this fatal disease.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.
2	Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 12:319–334. 2015.
3	Bussom S and Saif MW: Methods and rationale for the early detection of pancreatic cancer. Highlights from the ‘2010 ASCO Gastrointestinal Cancers Symposium’. Orlando, FL, USA: Orlando, FL, USA. January 22-24–2010, JOP 11: 128–130, 2010.
4	Shahrokni A and Saif MW: Metastatic pancreatic cancer: The dilemma of quality vs. quantity of life JOP. 14:391–394. 2013.
5	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016.
6	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011.
7	Okui M, Yamamichi T, Asakawa A, Harada M and Horio H: Resection for pancreatic cancer lung metastases. Korean J Thorac Cardiovasc Surg. 50:326–328. 2017.
8	Wu H, Kong L, Zhou S, Cui W, Xu F, Luo M, Li X, Tan Y and Miao L: The role of microRNAs in diabetic nephropathy. J Diabetes Res. 2014:9201342014.
9	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006.
10	Szymczyk A, Macheta A and Podhorecka M: Abnormal microRNA expression in the course of hematological malignancies. Cancer Manag Res. 10:4267–4277. 2018.
11	He L and Zhang H: MicroRNAs in the migration of mesenchymal stem cells. Stem Cell Rev. 15:3–12. 2019.
12	Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, Cai F, Ma L and Yu Y: The role of MicroRNAs in hepatocellular carcinoma. J Cancer. 9:3557–3569. 2018.
13	Delsin LEA, Salomao KB, Pezuk JA and Brassesco MS: Expression profiles and prognostic value of miRNAs in retinoblastoma. J Cancer Res Clin Oncol. 145:1–10. 2019.
14	Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S, Nourmohammadi P, Ghaderian SMH, Rasouli M and Mirzaei H: Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 233:8538–8550. 2018.
15	Bryzgunova OE, Konoshenko MY and Laktionov PP: MicroRNA-guided gene expression in prostate cancer: Literature and database overview. J Gene Med. 20:e30162018.
16	Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K, et al: MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci Rep. 7:423392017.
17	Li H, Xiang H, Ge W, Wang H, Wang T and Xiong M: Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 8:12313–12318. 2015.
18	Fan Y, Xu LL, Shi CY, Wei W, Wang DS and Cai DF: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Sci Rep. 6:227932016.
19	Cheng RF, Wang J, Zhang JY, Sun L, Zhao YR, Qiu ZQ, Sun BC and Sun Y: MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. Chin J Cancer. 35:642016.
20	Zhu G, Zhou L, Liu H, Shan Y and Zhang X: MicroRNA-224 promotes pancreatic cancer cell proliferation and migration by targeting the TXNIP-mediated HIF1α pathway. Cell Physiol Biochem. 48:1735–1746. 2018.
21	Fu Y, Liu X, Chen Q, Liu T, Lu C, Yu J, Miao Y and Wei J: Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. J Exp Clin Cancer Res. 37:1302018.
22	Li C, Dong Q, Che X, Xu L, Li Z, Fan Y, Hou K, Wang S, Qu J, Xu L, et al: MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. BMC Cancer. 18:6812018.
23	Ding Z, Jian S, Peng X, Liu Y, Wang J, Zheng L, Ou C, Wang Y, Zeng W and Zhou M: Loss of MiR-664 expression enhances cutaneous malignant melanoma proliferation by upregulating PLP2. Medicine (Baltimore). 94:e13272015.
24	Zhang YX, Qin LL and Yang SY: Down-regulation of miR-664 in cervical cancer is associated with lower overall survival. Eur Rev Med Pharmacol Sci. 20:1740–1744. 2016.
25	Fiala O, Pitule P, Hosek P, Liska V, Sorejs O, Bruha J, Vycital O, Buchler T, Poprach A, Topolcan O, et al: The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 39:10104283177092832017.
26	Wu L, Li Y, Li J and Ma D: MicroRNA-664 targets insulin receptor substrate 1 to suppress cell proliferation and invasion in breast cancer. Oncol Res. Mar 1–2018.Epub ahead of print:10.3727/096504018X15193500663936.
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
28	Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R and Lang D: PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 284:27524–27532. 2009.
29	Diao J, Su X, Cao L, Yang Y and Liu Y: MicroRNA 874 inhibits proliferation and invasion of pancreatic ductal adenocarcinoma cells by directly targeting paired box 6. Mol Med Rep. 18:1188–1196. 2018.
30	Li Y, Li Y, Liu Y, Xie P, Li F and Li G: PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells. Dig Dis Sci. 59:598–606. 2014.
31	Huang BS, Luo QZ, Han Y, Huang D, Tang QP and Wu LX: MiR-223/PAX6 axis regulates glioblastoma stem cell proliferation and the chemo resistance to TMZ via regulating PI3K/Akt pathway. J Cell Biochem. 118:3452–3461. 2017.
32	Li J and You X: MicroRNA 758 inhibits malignant progression of retinoblastoma by directly targeting PAX6. Oncol Rep. 40:1777–1786. 2018.
33	Passadouro M and Faneca H: Managing pancreatic adenocarcinoma: A special focus in microRNA gene therapy. Int J Mol Sci. 17:172016.
34	Yonemori K, Kurahara H, Maemura K and Natsugoe S: MicroRNA in pancreatic cancer. J Hum Genet. 62:33–40. 2017.
35	Sun L, Chua CY, Tian W, Zhang Z, Chiao PJ and Zhang W: MicroRNA signaling pathway network in pancreatic ductal adenocarcinoma. J Genet Genomics. 42:563–577. 2015.
36	Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, et al: microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer. 51:1389–1404. 2015.
37	Zhu H, Miao MH, Ji XQ, Xue J and Shao XJ: miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia. Biochem Biophys Res Commun. 459:340–345. 2015.
38	Bao Y, Chen B, Wu Q, Hu K, Xi X, Zhu W, Zhong X and Chen J: Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 17:51–58. 2017.
39	Chen B, Bao Y, Chen X, Yi J, Liu S, Fang Z, Zheng S and Chen J: Mir-664 promotes osteosarcoma cells proliferation via down-regulating of FOXO4. Biomed Pharmacother. 75:1–7. 2015.
40	Zhu X, Ju S, Yuan F, Chen G, Shu Y, Li C, Xu Y, Luo J and Xia L: microRNA-664 enhances proliferation, migration and invasion of lung cancer cells. Exp Ther Med. 13:3555–3562. 2017.
41	Yang Y, Liu H, Wang X and Chen L: Up-regulation of microRNA-664 inhibits cell growth and increases cisplatin sensitivity in cervical cancer. Int J Clin Exp Med. 8:18123–18129. 2015.
42	Fang Y, Zhang L, Li Z, Li Y, Huang C and Lu X: MicroRNAs in DNA damage response, carcinogenesis, and chemoresistance. Int Rev Cell Mol Biol. 333:1–49. 2017.
43	Meng Y, Zou Q, Liu T, Cai X, Huang Y and Pan J: microRNA-335 inhibits proliferation, cell-cycle progression, colony formation, and invasion via targeting PAX6 in breast cancer cells. Mol Med Rep. 11:379–385. 2015.
44	Zhao Y, Lu G, Ke X, Lu X, Wang X, Li H, Ren M and He S: miR-488 acts as a tumor suppressor gene in gastric cancer. Tumour Biol. 37:8691–8698. 2016.
45	Zhao X, Yue W, Zhang L, Ma L, Jia W, Qian Z, Zhang C and Wang Y: Downregulation of PAX6 by shRNA inhibits proliferation and cell cycle progression of human non-small cell lung cancer cell lines. PLoS One. 9:e857382014.
46	Li X, Yang L, Shuai T, Piao T and Wang R: MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016.
47	Xia X, Yin W, Zhang X, Yu X, Wang C, Xu S, Feng W and Yang H: PAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer. Oncol Lett. 10:1501–1506. 2015.
48	Wolin EM: PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 335:1–8. 2013.
49	Baer R, Cintas C, Therville N and Guillermet-Guibert J: Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter? Adv Biol Regul. 59:19–35. 2015.